Merck’s $10.8B Prometheus buyout can proceed after antitrust review

The government’s waiting period for Merck’s $10.8 billion Prometheus Biosciences buyout expired on Monday, meaning the companies can proceed to close the deal, according to an SEC filing. Prometheus announced the merger last month after fielding interest from several other pharma companies, including AbbVie and Bristol Myers Squibb, according to…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.